Comparison of the dual receptor endothelin antagonist enrasentan with enalapril in asymptomatic left ventricular systolic dysfunction: a cardiovascular magnetic resonance study
| Autor: | Sanjay K Prasad, Bjoern A. Groenning, Gillian Smith, Marianne M Barlow, Henry J. Dargie, Frank Grothues, John G.F. Cleland, Dudley J. Pennell |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male medicine.medical_specialty Carboxylic Acids Cardiac index Angiotensin-Converting Enzyme Inhibitors Cardiovascular Medicine Asymptomatic Ventricular Dysfunction Left Enalapril Internal medicine medicine Humans Ventricular remodeling Aged Heart Failure Neurotransmitter Agents Ventricular Remodeling business.industry Middle Aged medicine.disease Brain natriuretic peptide Treatment Outcome Heart failure Indans Disease Progression Cardiology End-diastolic volume Female medicine.symptom Cardiology and Cardiovascular Medicine Endothelin receptor business Magnetic Resonance Angiography medicine.drug |
| Zdroj: | Heart. 92:798-803 |
| ISSN: | 1355-6037 |
| DOI: | 10.1136/hrt.2004.049734 |
| Popis: | Objective: To compare the effect of the dual endothelin A/B receptor antagonist enrasentan with enalapril on left ventricular (LV) remodelling. Methods: Multicentre, randomised, double blind, parallel group study of 72 asymptomatic patients with LV dysfunction. Patients received enrasentan (60–90 mg/day) or enalapril (10–20 mg/day). The primary end point was the change in LV end diastolic volume index (EDVI) after six months’ treatment. Results: LV EDVI increased with enrasentan but decreased with enalapril (3.9 (1.8) v −3.4 (1.4) ml/m 2 , p = 0.001). Enrasentan increased resting cardiac index compared with enalapril (0.11 (0.07) v −0.10 (0.07) l/m 2 , p = 0.04), as well as LV mass index (0.67 (1.6) v −3.6 (1.6) g/m 2 , p = 0.04). Other variables were comparable between groups. Enalapril lowered brain natriuretic peptide more than enrasentan (–19.3 (9.4) v –5.8 (6.9) pg/ml, p = 0.005). Noradrenaline (norepinephrine) (p = 0.02) increased more with enrasentan than with enalapril. Enrasentan was associated with more serious adverse events compared with enalapril (six (16.7%) patients v one (2.8%), p = 0.02); the rate of progression of heart failure did not differ. Conclusion: In asymptomatic patients with LV dysfunction, LV EDVI increased over six months with enrasentan compared with enalapril treatment, with adverse neurohormonal effects. This suggests that enrasentan at a dose of 60–90 mg/day over six months causes adverse ventricular remodelling despite an increase in the resting cardiac index. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|